8-K: Accendra Health Reports Q2 Results, CEO to Retire

Accendra Health announced second quarter 2026 financial results, reporting a decrease in net revenue and an increase in net loss, alongside the news of CEO Edward Pesicka's planned retirement by year-end.

Summary

• Accendra Health reported a net revenue of $613.2 million for the second quarter of 2026, a decrease from $681.9 million in the same period of 2025.
• The company reported a net loss from continuing operations of $89.1 million for Q2 2026, compared to a loss of $83.8 million in Q2 2025.
• Adjusted EBITDA for Q2 2026 was $60.1 million, down from $96.6 million in Q2 2025.
• Free cash flow for Q2 2026 was a negative $25.1 million, compared to a positive $15.2 million in Q2 2025.
• Total debt was reduced by $385 million in the second quarter through a balance sheet optimization transaction.
• CEO Edward Pesicka announced his intention to retire by the end of 2026, with the Board initiating a succession planning process.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue decline, increased losses, and the CEO's impending retirement, despite efforts to reduce debt.

Positives

• Reduced total debt by $385 million in the second quarter through a balance sheet optimization transaction.
• Successfully completed a large commercial payor exit, eliminating over $125 million in annualized operating expenses.
• Initiated a nationwide rollout of the Sleep Center of Excellence.
• Secured new strategic partnerships with potential for topline and bottom line expansion starting late 2026.

Negatives

• Net revenue decreased to $613.2 million in Q2 2026 from $681.9 million in Q2 2025.
• Net loss from continuing operations increased to $89.1 million in Q2 2026 from $83.8 million in Q2 2025.
• Adjusted EBITDA decreased to $60.1 million in Q2 2026 from $96.6 million in Q2 2025.
• Free cash flow turned negative at $(25.1) million in Q2 2026, compared to positive $15.2 million in Q2 2025.
• Year-to-date net revenue decreased to $1,241.0 million in 2026 from $1,355.8 million in 2025.
• Year-to-date net loss from continuing operations increased to $95.5 million in 2026 from $87.6 million in 2025.
• Year-to-date Adjusted EBITDA decreased to $118.5 million in 2026 from $192.7 million in 2025.
• Year-to-date free cash flow turned negative at $(27.1) million in 2026, compared to positive $50.7 million in 2025.

Risks

• Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from projections.
• The company's ability to address macro and market conditions is subject to risks.
• The succession planning process for the next President and CEO introduces uncertainty regarding the timeline for selection and appointment.

Future Outlook

The company is updating its full-year 2026 financial guidance to $2.45 billion $2.55 billion in revenue, $300 million $320 million in Adjusted EBITDA, and breakeven to slightly positive free cash flow.

Management Comments

• "Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exit behind us."
• "In the last six months, we have eliminated well over $125 million of annualized operating expense directly associated with this large commercial payor, and we are now beginning to reset our business for accelerated future growth."
• "Additionally, we reduced outstanding debt by $385 million and comprehensively reset our debt maturity profile through our balance sheet optimization transaction which closed in June."
• "We also saw continued progress on key growth initiatives and new strategic partnerships that have both topline and bottom line expansion opportunities that will begin to emerge in late 2026 and accelerate in 2027."
• "These include the nationwide rollout of the Sleep Center of Excellence, new commercial agreements, and an increased emphasis on expense rationalization."
• "President & CEO Edward A. Pesicka has informed the Board of Directors that he intends to retire from his role by the end of 2026. Pesicka also plans to step down from the Board of Directors before the year's end."

Industry Context

StockSavvy.ai notes that Accendra Health operates in the home-based care sector, which is undergoing significant transformation due to payor consolidation, evolving reimbursement models, and the increasing demand for chronic condition management outside traditional hospital settings. The company's strategic focus on 'health beyond the hospital' and its brands like Apria and Byram position it within this evolving landscape.

Management Changes

Stakeholder Impact

• Shareholders: Potential negative impact due to declining revenues, increasing losses, and CEO retirement uncertainty, although debt reduction is a positive.
• Employees: The CEO transition may lead to strategic shifts that could affect employee roles and company direction.
• Creditors: Positive impact from the significant reduction in total debt, improving the company's leverage profile.

Next Steps

• The Board of Directors will leverage its succession planning process to select a successor for the President and CEO role.
• Edward Pesicka will continue to lead the business and facilitate a smooth transition during the selection period.
• The company expects to see emerging topline and bottom line expansion opportunities in late 2026 and accelerating in 2027 from growth initiatives.
• Nationwide rollout of the Sleep Center of Excellence.

Key Dates

Recommendation

The company is facing significant headwinds with declining revenue and increasing losses, coupled with the uncertainty of a CEO transition. While debt reduction is a positive step, the overall financial performance and strategic outlook warrant a cautious 'hold' rating until a new CEO is in place and a clearer path to recovery is demonstrated.

Keywords

Accendra Health, Q2 2026, Financial Results, Adjusted EBITDA, Free Cash Flow, Debt Reduction, CEO Retirement, Continuing Operations